Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma
Glaucoma is a degenerative, chronic ocular disease that causes irreversible vision loss. The major symptom of glaucoma is high intraocular pressure, which happens when the flow of aqueous humor between the front and back of the eye is blocked. Glaucoma therapy is challenging because of the low bioav...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/2/681 |
| _version_ | 1827755927904714752 |
|---|---|
| author | Hassan A. Albarqi Anuj Garg Mohammad Zaki Ahmad Abdulsalam A. Alqahtani Ismail A. Walbi Javed Ahmad |
| author_facet | Hassan A. Albarqi Anuj Garg Mohammad Zaki Ahmad Abdulsalam A. Alqahtani Ismail A. Walbi Javed Ahmad |
| author_sort | Hassan A. Albarqi |
| collection | DOAJ |
| description | Glaucoma is a degenerative, chronic ocular disease that causes irreversible vision loss. The major symptom of glaucoma is high intraocular pressure, which happens when the flow of aqueous humor between the front and back of the eye is blocked. Glaucoma therapy is challenging because of the low bioavailability of drugs from conventional ocular drug delivery systems such as eye drops, ointments, and gels. The low bioavailability of antiglaucoma agents could be due to the precorneal and corneal barriers as well as the low biopharmaceutical attributes of the drugs. These limitations can be overcome by employing nanoparticulate drug delivery systems. Over the last decade, there has been a lot of interest in chitosan-based nanoparticulate systems to overcome the limitations (such as poor residence time, low corneal permeability, etc.) associated with conventional ocular pharmaceutical products. Therefore, the main aim of the present manuscript is to review the recent research work involving the chitosan-based nanoparticulate system to treat glaucoma. It discusses the significance of the chitosan-based nanoparticulate system, which provides mucoadhesion to improve the residence time of drugs and their ocular bioavailability. Furthermore, different types of chitosan-based nanoparticulate systems are also discussed, namely nanoparticles of chitosan core only, nanoparticles coated with chitosan, and hybrid nanoparticles of chitosan. The manuscript also provides a critical analysis of contemporary research related to the impact of this chitosan-based nanomedicine on the corneal permeability, ocular bioavailability, and therapeutic performance of loaded antiglaucoma agents. |
| first_indexed | 2024-03-11T08:15:53Z |
| format | Article |
| id | doaj.art-7f2f3049682b49a98f8d715c50134bf4 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T08:15:53Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-7f2f3049682b49a98f8d715c50134bf42023-11-16T22:43:11ZengMDPI AGPharmaceutics1999-49232023-02-0115268110.3390/pharmaceutics15020681Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in GlaucomaHassan A. Albarqi0Anuj Garg1Mohammad Zaki Ahmad2Abdulsalam A. Alqahtani3Ismail A. Walbi4Javed Ahmad5Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi ArabiaInstitute of Pharmaceutical Research, GLA University, Mathura 281406, IndiaDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Najran University, Najran 11001, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi ArabiaGlaucoma is a degenerative, chronic ocular disease that causes irreversible vision loss. The major symptom of glaucoma is high intraocular pressure, which happens when the flow of aqueous humor between the front and back of the eye is blocked. Glaucoma therapy is challenging because of the low bioavailability of drugs from conventional ocular drug delivery systems such as eye drops, ointments, and gels. The low bioavailability of antiglaucoma agents could be due to the precorneal and corneal barriers as well as the low biopharmaceutical attributes of the drugs. These limitations can be overcome by employing nanoparticulate drug delivery systems. Over the last decade, there has been a lot of interest in chitosan-based nanoparticulate systems to overcome the limitations (such as poor residence time, low corneal permeability, etc.) associated with conventional ocular pharmaceutical products. Therefore, the main aim of the present manuscript is to review the recent research work involving the chitosan-based nanoparticulate system to treat glaucoma. It discusses the significance of the chitosan-based nanoparticulate system, which provides mucoadhesion to improve the residence time of drugs and their ocular bioavailability. Furthermore, different types of chitosan-based nanoparticulate systems are also discussed, namely nanoparticles of chitosan core only, nanoparticles coated with chitosan, and hybrid nanoparticles of chitosan. The manuscript also provides a critical analysis of contemporary research related to the impact of this chitosan-based nanomedicine on the corneal permeability, ocular bioavailability, and therapeutic performance of loaded antiglaucoma agents.https://www.mdpi.com/1999-4923/15/2/681glaucomachitosannanoparticlesmucoadhesionocular bioavailabilitytherapeutic efficacy |
| spellingShingle | Hassan A. Albarqi Anuj Garg Mohammad Zaki Ahmad Abdulsalam A. Alqahtani Ismail A. Walbi Javed Ahmad Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma Pharmaceutics glaucoma chitosan nanoparticles mucoadhesion ocular bioavailability therapeutic efficacy |
| title | Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma |
| title_full | Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma |
| title_fullStr | Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma |
| title_full_unstemmed | Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma |
| title_short | Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma |
| title_sort | recent progress in chitosan based nanomedicine for its ocular application in glaucoma |
| topic | glaucoma chitosan nanoparticles mucoadhesion ocular bioavailability therapeutic efficacy |
| url | https://www.mdpi.com/1999-4923/15/2/681 |
| work_keys_str_mv | AT hassanaalbarqi recentprogressinchitosanbasednanomedicineforitsocularapplicationinglaucoma AT anujgarg recentprogressinchitosanbasednanomedicineforitsocularapplicationinglaucoma AT mohammadzakiahmad recentprogressinchitosanbasednanomedicineforitsocularapplicationinglaucoma AT abdulsalamaalqahtani recentprogressinchitosanbasednanomedicineforitsocularapplicationinglaucoma AT ismailawalbi recentprogressinchitosanbasednanomedicineforitsocularapplicationinglaucoma AT javedahmad recentprogressinchitosanbasednanomedicineforitsocularapplicationinglaucoma |